Amendments to the Claims

1. (Currently amended) A method of treating depression or pain in a mammal comprising administering to a mammal in need of such treatment an effective amount of a

[A] compound of formula (I)



(I)

wherein

n is 1, 2 or 3;

R1 is C_2-C_{10}alkyl, C_2-C_{10}alkenyl, C_3-C_8cycloalkyl, C_3-C_8cycloalkenyl, C_4-C_{10}cycloalkylalkyl or C_4-C_{10}cycloalkenylalkyl wherein one $-CH_2-$ within any cycloalkyl moiety is optionally substituted by -O- or -S- and wherein each group is optionally substituted with from 1 to 7 halogen substituents and/or with from 1 to 3 substituents each independently selected from hydroxy, cyano, C_1-C_4alkyl, C_1-C_4alkylthio (optionally substituted with from 1 to 3 halogen atoms) and C_1-C_4alkoxy (optionally substituted with from 1 to 3 halogen atoms);

R2 is independently at each occurrence selected from H and C_1-C_4alkyl;

R3 is H or C_1-C_4alkyl;

R4 is H, halogen, hydroxy, cyano, C_1-C_4alkyl or C_1-C_4alkoxy;

R5 is H, halogen, hydroxy, cyano, C_1-C_4alkyl or C_1-C_4alkoxy; and

Heteroaryl is

(i) a 5- or 6-membered monocyclic heteroaromatic group optionally substituted with 1, 2, 3 or 4 substituents (depending on the number of available substitution positions) each independently selected from halo, cyano, C_1-C_4alkyl (optionally substituted with 1, 2 or 3 F atoms), C_1-C_4alkoxy (optionally substituted with 1, 2 or 3 F atoms) and C_1-C_4alkylthio (optionally substituted with 1, 2 or 3 F atoms) and/or with

1 substituent selected from pyridinyl, pyrazolyl, phenyl (optionally substituted with 1, 2 or 3 halo substituents), benzyl (optionally substituted with 1, 2 or 3 halo substituents) and phenoxy (optionally substituted with 1, 2 or 3 halo substituents) with the proviso that only C_1-C_4alkyl may be a substituent for the H of any -NH- moiety present within the group, or

(ii) an 8-, 9- or 10-membered bicyclic heteroaromatic group optionally substituted with 1, 2, 3, 4, 5 or 6 substituents (depending on the number of available substitution positions) each independently selected from halo, cyano, C_1-C_4alkyl (optionally substituted with 1, 2 or 3 F atoms), C_1-C_4alkoxy (optionally substituted with 1, 2 or 3 F atoms) and C_1-C_4alkylthio (optionally substituted with 1, 2 or 3 F atoms) with the proviso that only C_1-C_4alkyl may be a substituent for the H of any -NH- moiety present within the group;

or a pharmaceutically acceptable salt thereof [,for use in a method for treatment of the human or animal body by therapy].

2. (Original) A compound of formula (I)



(I)

wherein

n is 1, 2 or 3;

R1 is C_2-C_{10}alkyl, C_2-C_{10}alkenyl, C_3-C_8cycloalkyl, C_3-C_8cycloalkenyl, C_4-C_{10}cycloalkylalkyl or C_4-C_{10}cycloalkenylalkyl wherein one $-CH_2-$ within any cycloalkyl moiety is optionally substituted by -O- or -S- and wherein each group is optionally substituted with from 1 to 7 halogen substituents and/or with from 1 to 3 substituents each independently selected from hydroxy, cyano, C_1-C_4alkyl, C_1-C_4alkylthio (optionally substituted with

from 1 to 3 halogen atoms) and C_1-C_4alkoxy (optionally substituted with from 1 to 3 halogen atoms);

R2 is independently at each occurrence selected from H and C_1-C_4alkyl;

R3 is H or C_1-C_4alkyl;

R4 is H, halogen, hydroxy, cyano, C_1-C_4alkyl or C_1-C_4alkoxy;

R5 is H, halogen, hydroxy, cyano, C_1-C_4alkyl or C_1-C_4alkoxy; and

Heteroaryl is

(i) a 5- or 6-membered monocyclic heteroaromatic group optionally substituted with 1, 2, 3 or 4 substituents (depending on the number of available substitution positions) each independently selected from halo, cyano, C_1-C_4alkyl (optionally substituted with 1, 2 or 3 F atoms), C_1-C_4alkoxy (optionally substituted with 1, 2 or 3 F atoms) and C_1-C_4alkylthio (optionally substituted with 1, 2 or 3 F atoms) and/or with 1 substituent selected from pyridinyl, pyrazolyl, phenyl (optionally substituted with 1, 2 or 3 halo substituents), benzyl (optionally substituted with 1, 2 or 3 halo substituents) and phenoxy (optionally substituted with 1, 2 or 3 halo substituents) with the proviso that only C_1-C_4alkyl may be a substituent for the H of any -NH- moiety present within the group, or

(ii) an 8-, 9- or 10-membered bicyclic heteroaromatic group optionally substituted with 1, 2, 3, 4, 5 or 6 substituents (depending on the number of available substitution positions) each independently selected from halo, cyano, C_1-C_4alkyl (optionally substituted with 1, 2 or 3 F atoms), C_1-C_4alkoxy (optionally substituted with 1, 2 or 3 F atoms) and C_1-C_4alkylthio (optionally substituted with 1, 2 or 3 F atoms) with the proviso that only C_1-C_4alkyl may be a substituent for the H of any -NH- moiety present within the group;

or a pharmaceutically acceptable salt thereof, with the proviso that the compounds





and

are excluded.

3. (Currently amended) A compound as claimed in [Claim 1 or] Claim 2 wherein n is 1.

4. (Currently amended) A compound as claimed in [any preceding] Claims 2 or 3 wherein R2 [is H], R3 [is H], R4 [is H] and R5 [is] are H.
5. (Canceled)
6. (Canceled)
7. (Canceled)

8. (Currently amended) A compound as claimed in any one of Claims [1 to 7] 2 or 3 wherein R1 is C_2-C_{10}alkyl optionally substituted with from 1 to 7 halogen substituents and/or with from 1 to 3 substituents each independently selected from hydroxy, cyano, C_1-C_4alkyl, C_1-C_4alkylthio (optionally substituted with from 1 to 3 halogen atoms) and C_1-C_4alkoxy (optionally substituted with from 1 to 3 halogen atoms).

9. (Currently amended) A compound as claimed in any one of Claims [1 to 7] 2 or 3 wherein R1 is C_4-C_{10}cycloalkylalkyl wherein one $-CH_2-$ within the cycloalkyl moiety is optionally substituted by -O- or -S- and wherein the group is optionally substituted with from 1 to 7 halogen substituents and/or with from 1 to 3 substituents each independently selected from hydroxy, cyano, C_1-C_4alkyl, C_1-C_4alkylthio (optionally substituted with from 1 to 3 halogen atoms) and C_1-C_4alkoxy (optionally substituted with from 1 to 3 halogen atoms).

10. (Currently amended) A compound as claimed in any one of Claims [1 to 9] 2 or 3 wherein Heteroaryl is a 5- or 6-membered monocyclic heteroaromatic group

optionally substituted with 1, 2, 3 or 4 substituents (depending on the number of available substitution positions) each independently selected from halo, cyano, C_1-C_4alkyl (optionally substituted with 1, 2 or 3 F atoms), C_1-C_4alkoxy (optionally substituted with 1, 2 or 3 F atoms) and C_1-C_4alkylthio (optionally substituted with 1, 2 or 3 F atoms) and/or with 1 substituent selected from pyridinyl, pyrazolyl, phenyl (optionally substituted with 1, 2 or 3 halo substituents), benzyl (optionally substituted with 1, 2 or 3 halo substituents) and phenoxy (optionally substituted with 1, 2 or 3 halo substituents) with the proviso that only C_1-C_4alkyl may be a substituent for the H of any -NH- moiety present within the group.

11. (Canceled)

12. (Canceled)

13. (Currently amended) A compound as claimed in any one of Claims [1 to 9] 2 or 3 wherein Heteroaryl is an 8-, 9- or 10-membered bicyclic heteroaromatic group optionally substituted with 1, 2, 3, 4, 5 or 6 substituents (depending on the number of available substitution positions) each independently selected from halo, cyano, C_1-C_4 alkyl (optionally substituted with 1, 2 or 3 F atoms), C_1-C_4alkoxy (optionally substituted with 1, 2 or 3 F atoms) and C_1-C_4thioalkyl (optionally substituted with 1, 2 or 3 F atoms) with the proviso that only C_1-C_4alkyl may be a substituent for the H of any -NH- moiety present within the group.

14. (Canceled)

15. (Canceled)

16. (Currently amended) A pharmaceutical composition comprising a compound of formula (I) as defined in Claim [1] 2, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable diluent, excipient or carrier.

17. (Canceled)

18. (Canceled)